Research ArticleArticle
A Strategy for Assessing Potential Drug-Drug Interactions of a Concomitant Agent against a Drug Absorbed via an Intestinal Transporter in Humans
Akiko Mizuno-Yasuhira, Yasuhiro Nakai, Emi Gunji, Saeko Uchida, Teisuke Takahashi, Kohnosuke Kinoshita, Shigeji Jingu, Soichi Sakai, Yoshishige Samukawa and Jun-ichi Yamaguchi
Drug Metabolism and Disposition September 2014, 42 (9) 1456-1465; DOI: https://doi.org/10.1124/dmd.114.058305
Akiko Mizuno-Yasuhira
Departments of Drug Safety and Pharmacokinetics Laboratories, Saitama, Japan (A.M.-Y., K.K., S.J., J.Y.) and Molecular Function and Pharmacology Laboratories (E.G., S.U., T.T.), Taisho Pharmaceutical Co., Ltd., Saitama, Japan; Departments of Development Headquarters, (Y.N., Y.S.); and Clinical Research (S.S.), Taisho Pharmaceutical Co. Ltd., Tokyo, Japan (S.S.)
Yasuhiro Nakai
Departments of Drug Safety and Pharmacokinetics Laboratories, Saitama, Japan (A.M.-Y., K.K., S.J., J.Y.) and Molecular Function and Pharmacology Laboratories (E.G., S.U., T.T.), Taisho Pharmaceutical Co., Ltd., Saitama, Japan; Departments of Development Headquarters, (Y.N., Y.S.); and Clinical Research (S.S.), Taisho Pharmaceutical Co. Ltd., Tokyo, Japan (S.S.)
Emi Gunji
Departments of Drug Safety and Pharmacokinetics Laboratories, Saitama, Japan (A.M.-Y., K.K., S.J., J.Y.) and Molecular Function and Pharmacology Laboratories (E.G., S.U., T.T.), Taisho Pharmaceutical Co., Ltd., Saitama, Japan; Departments of Development Headquarters, (Y.N., Y.S.); and Clinical Research (S.S.), Taisho Pharmaceutical Co. Ltd., Tokyo, Japan (S.S.)
Saeko Uchida
Departments of Drug Safety and Pharmacokinetics Laboratories, Saitama, Japan (A.M.-Y., K.K., S.J., J.Y.) and Molecular Function and Pharmacology Laboratories (E.G., S.U., T.T.), Taisho Pharmaceutical Co., Ltd., Saitama, Japan; Departments of Development Headquarters, (Y.N., Y.S.); and Clinical Research (S.S.), Taisho Pharmaceutical Co. Ltd., Tokyo, Japan (S.S.)
Teisuke Takahashi
Departments of Drug Safety and Pharmacokinetics Laboratories, Saitama, Japan (A.M.-Y., K.K., S.J., J.Y.) and Molecular Function and Pharmacology Laboratories (E.G., S.U., T.T.), Taisho Pharmaceutical Co., Ltd., Saitama, Japan; Departments of Development Headquarters, (Y.N., Y.S.); and Clinical Research (S.S.), Taisho Pharmaceutical Co. Ltd., Tokyo, Japan (S.S.)
Kohnosuke Kinoshita
Departments of Drug Safety and Pharmacokinetics Laboratories, Saitama, Japan (A.M.-Y., K.K., S.J., J.Y.) and Molecular Function and Pharmacology Laboratories (E.G., S.U., T.T.), Taisho Pharmaceutical Co., Ltd., Saitama, Japan; Departments of Development Headquarters, (Y.N., Y.S.); and Clinical Research (S.S.), Taisho Pharmaceutical Co. Ltd., Tokyo, Japan (S.S.)
Shigeji Jingu
Departments of Drug Safety and Pharmacokinetics Laboratories, Saitama, Japan (A.M.-Y., K.K., S.J., J.Y.) and Molecular Function and Pharmacology Laboratories (E.G., S.U., T.T.), Taisho Pharmaceutical Co., Ltd., Saitama, Japan; Departments of Development Headquarters, (Y.N., Y.S.); and Clinical Research (S.S.), Taisho Pharmaceutical Co. Ltd., Tokyo, Japan (S.S.)
Soichi Sakai
Departments of Drug Safety and Pharmacokinetics Laboratories, Saitama, Japan (A.M.-Y., K.K., S.J., J.Y.) and Molecular Function and Pharmacology Laboratories (E.G., S.U., T.T.), Taisho Pharmaceutical Co., Ltd., Saitama, Japan; Departments of Development Headquarters, (Y.N., Y.S.); and Clinical Research (S.S.), Taisho Pharmaceutical Co. Ltd., Tokyo, Japan (S.S.)
Yoshishige Samukawa
Departments of Drug Safety and Pharmacokinetics Laboratories, Saitama, Japan (A.M.-Y., K.K., S.J., J.Y.) and Molecular Function and Pharmacology Laboratories (E.G., S.U., T.T.), Taisho Pharmaceutical Co., Ltd., Saitama, Japan; Departments of Development Headquarters, (Y.N., Y.S.); and Clinical Research (S.S.), Taisho Pharmaceutical Co. Ltd., Tokyo, Japan (S.S.)
Jun-ichi Yamaguchi
Departments of Drug Safety and Pharmacokinetics Laboratories, Saitama, Japan (A.M.-Y., K.K., S.J., J.Y.) and Molecular Function and Pharmacology Laboratories (E.G., S.U., T.T.), Taisho Pharmaceutical Co., Ltd., Saitama, Japan; Departments of Development Headquarters, (Y.N., Y.S.); and Clinical Research (S.S.), Taisho Pharmaceutical Co. Ltd., Tokyo, Japan (S.S.)
DMD articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|
Log in using your username and password
Purchase access
You may purchase access to this article. This will require you to create an account if you don't already have one.
In this issue
Research ArticleArticle
Prediction of Transporter-Mediated DDI Using a Dynamic Model
Akiko Mizuno-Yasuhira, Yasuhiro Nakai, Emi Gunji, Saeko Uchida, Teisuke Takahashi, Kohnosuke Kinoshita, Shigeji Jingu, Soichi Sakai, Yoshishige Samukawa and Jun-ichi Yamaguchi
Drug Metabolism and Disposition September 1, 2014, 42 (9) 1456-1465; DOI: https://doi.org/10.1124/dmd.114.058305
Research ArticleArticle
Prediction of Transporter-Mediated DDI Using a Dynamic Model
Akiko Mizuno-Yasuhira, Yasuhiro Nakai, Emi Gunji, Saeko Uchida, Teisuke Takahashi, Kohnosuke Kinoshita, Shigeji Jingu, Soichi Sakai, Yoshishige Samukawa and Jun-ichi Yamaguchi
Drug Metabolism and Disposition September 1, 2014, 42 (9) 1456-1465; DOI: https://doi.org/10.1124/dmd.114.058305
Jump to section
Related Articles
Cited By...
More in this TOC Section
Similar Articles
Advertisement